Apogee Therapeutics, Inc. (APGE)
NASDAQ: APGE · IEX Real-Time Price · USD
47.50
-0.02 (-0.04%)
At close: Jul 19, 2024, 4:00 PM
47.52
+0.02 (0.04%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Apogee Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Apogee Therapeutics stock have an average target of 65.8, with a low estimate of 40 and a high estimate of 91. The average target predicts an increase of 38.53% from the current stock price of 47.50.
Analyst Consensus: Strong Buy
* Price targets were last updated on May 10, 2024.
Analyst Ratings
The average analyst rating for APGE stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 4 | 4 | 4 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| B of A Securities | B of A Securities | Strong Buy Initiates $80 | Strong Buy | Initiates | $80 | +68.42% | May 10, 2024 |
| Jefferies | Jefferies | Strong Buy Maintains $37 → $75 | Strong Buy | Maintains | $37 → $75 | +57.89% | Mar 6, 2024 |
| Stifel | Stifel | Strong Buy Maintains $46 → $95 | Strong Buy | Maintains | $46 → $95 | +100.00% | Mar 5, 2024 |
| Guggenheim | Guggenheim | Strong Buy Maintains $44 → $91 | Strong Buy | Maintains | $44 → $91 | +91.58% | Mar 5, 2024 |
| Guggenheim | Guggenheim | Strong Buy Maintains $29 → $44 | Strong Buy | Maintains | $29 → $44 | -7.37% | Jan 3, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-2.73
from -3.36
EPS Next Year
-3.35
from -2.73
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | n/a | n/a | 6.3M | 581.7M |
| Avg | n/a | n/a | n/a | 1.5M | 141.3M |
| Low | n/a | n/a | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | 37,919.6% |
| Avg | - | - | - | - | 9,133.3% |
| Low | - | - | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -2.37 | -2.50 | -2.35 | -3.05 | -3.80 |
| Avg | -2.73 | -3.35 | -4.06 | -2.96 | -3.69 |
| Low | -3.09 | -5.40 | -6.75 | -2.84 | -3.55 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.